Abzyme Therapeutics LLC

Pottstown, PA

UEI
H2MLEFWV36N6
CAGE
62ES6
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • For Profit Organization
  • Asian-Pacific American Owned
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
321 Jones Blvd #300, Pottstown, PA 19464, USA
Website
abzymetx.com
Founded
2010
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
The objective of this contract is to develop camelid vhhs that are capable of significantly (at least 5-fold… 75N93019C00009 National Institute of Allergy and Infectious Diseases (NIH) $299,815
Monoclonal antibodies to RNA-modifications (MOONSHOT) 75N91018C00031 National Cancer Institute (NIH) $299,999
R & D exempt W911QY18C0004 ACC Aberdeen Proving Ground $999,998
Purchase Order W911QY16P0229 ACC Aberdeen Proving Ground $149,657
Purchase Order W911QY16P0050 ACC Aberdeen Proving Ground $99,988

Grant awards

Award Agency Obligated Awarded
Novel immune-escape uricase for treatment of hyperuricemia R43AI174703 National Institute of Allergy and Infectious Diseases (NIH) $299,999
Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis R43NS120624 National Institute of Neurological Disorders and Stroke (NIH) $1,197,321
Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases R44EY030821 National Eye Institute (NIH) $3,315,988
Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases R43EY030821 National Eye Institute (NIH) $299,989
Pemphigus-specific T cell engagers for pemphigus targeted immunotherapy R43AI151635 National Institute of Allergy and Infectious Diseases (NIH) $280,352

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

Vendor Location Primary NAICS
Oncotrap Inc. UEI KX22VNNMBYZ3 Chapel Hill, NC 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Larix Bioscience LLC UEI H3QRCCS8FK49 Sunnyvale, CA —
Novab, Inc. UEI WKYDVLA9B616 Tucker, GA 621511 Medical Laboratories
Digital Proteomics UEI TYHDLNB65NJ1 San Diego, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Antagen Biosciences Inc. UEI HXD6EFH2ND57 Canton, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Abzyme Therapeutics LLC is a biopharmaceutical company that develops modular antibody fragments for immunotherapy. Through federal contracts, the company has provided research and development services related to enhancing HIV gp120 protein production using camelid VHH antibodies. This was funded by the NIH's National Institute of Allergy and Infectious Diseases as a Small Business Innovation Research program Phase I contract.

Abzyme Therapeutics LLC has received multiple federal grants to develop novel therapeutics. This includes an NIH National Institute of Neurological Disorders and Stroke grant to engineer brain-penetrating bispecific antibodies to inhibit complement activation and stimulate nerve growth for treating progressive multiple sclerosis. Additionally, Abzyme Therapeutics LLC has received NIH National Eye Institute and NIH National Institute of Allergy and Infectious Diseases grants to develop multi-specific antibodies targeting retinal neovascular diseases and pemphigus, respectively. The grants fall under the NIH's Extramural Research Programs supporting research in specialized areas.

SBA capabilities narrative

From the vendor's SBA profile

Provide services in recombinant antibody development, modification and production services

Quick answers

Is Abzyme Therapeutics LLC registered in SAM.gov?

Yes. Abzyme Therapeutics LLC's SAM.gov registration is active through January 2, 2027.

What is Abzyme Therapeutics LLC's CAGE code?

Abzyme Therapeutics LLC's CAGE code is 62ES6, and its Unique Entity ID (UEI) is H2MLEFWV36N6.

What is Abzyme Therapeutics LLC's most recent federal award?

Abzyme Therapeutics LLC's most recent federal grant award is Novel immune-escape uricase for treatment of hyperuricemia (R43AI174703), from National Institute of Allergy and Infectious Diseases (NIH), on May 22, 2023.

On GovTribe

See Abzyme Therapeutics LLC's full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe